Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC, USA.
Department of Pathology, Wake Forest School of Medicine, Winston-Salem, NC, USA.
J Dermatolog Treat. 2022 Feb;33(1):512-517. doi: 10.1080/09546634.2020.1770170. Epub 2020 May 25.
Systemic methotrexate (MTX) is a useful treatment for many dermatologic conditions, however, the risk of adverse events prevents its use in patients with minimal or localized disease. Topical application of MTX may be an option to avoid the systemic adverse effects of oral MTX.
To assess what is known about the efficacy and safety of topical methotrexate.
A search on Pubmed was conducted. There were no limits on publication date.
A total of 963 articles were discovered. Using our exclusion criteria, 916 articles were excluded; 47 articles were used for full text assessment. Topical MTX has been used primarily in psoriasis but also in mycosis fungoides, lymphomatoid papulosis, and oral precancerous lesions. Optimal delivery system and formulation for adequate penetration is still under investigation.
The quality of evidence for the utility of topical methotrexate in psoriasis is good, however, for other dermatologic diseases, the quality is poor. Topical MTX with improved delivery methods may be a viable tool against certain localized dermatologic conditions for patients who do not tolerate oral MTX. Further double-blinded randomized controled studies are needed to substantiate the utility of topical methotrexate.
甲氨蝶呤(MTX)是治疗许多皮肤科疾病的有效药物,但由于其全身性不良反应,限制了它在轻度或局限性疾病患者中的使用。局部应用 MTX 可能是避免口服 MTX 全身不良反应的一种选择。
评估局部用甲氨蝶呤的疗效和安全性。
在 Pubmed 上进行了检索。未对发表日期进行限制。
共发现 963 篇文章。使用我们的排除标准,排除了 916 篇文章;有 47 篇文章进行了全文评估。局部 MTX 主要用于治疗银屑病,但也用于蕈样真菌病、淋巴样丘疹病和口腔癌前病变。最佳的传递系统和配方以实现充分渗透仍在研究中。
局部用甲氨蝶呤治疗银屑病的证据质量良好,但对于其他皮肤科疾病,证据质量较差。对于不能耐受口服 MTX 的患者,具有改进传递方法的局部 MTX 可能是治疗某些局限性皮肤病的有效工具。需要进一步的双盲随机对照研究来证实局部用甲氨蝶呤的效用。